These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30783954)

  • 1. Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
    Chen YC; Lin FY; Lin YW; Cheng SM; Chang CC; Lin RH; Chuang CL; Sheu JS; Chen SM; Tsai CS
    Cardiovasc Drugs Ther; 2019 Apr; 33(2):129-137. PubMed ID: 30783954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
    Chen YC; Lin FY; Lin YW; Cheng SM; Lin RH; Chuang CL; Sheu JS; Chen SM; Chang CC; Tsai CS
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):75-86. PubMed ID: 30467686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
    Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
    Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
    Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
    Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Course of platelet miRNAs after cessation of P2Y12 antagonists.
    Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
    Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease.
    Hu X; Li M; Li H; Song P; Zhang Y; Zhou G; Tang J; Peng L; Ma Q; Chen X
    Platelets; 2023 Dec; 34(1):2200860. PubMed ID: 37070954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
    Giustino G; Redfors B; Kirtane AJ; Mehran R; Dangas GD; Witzenbichler B; Neumann FJ; Weisz G; Généreux P; Maehara A; McAndrew T; Farhan S; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Gurbel P; Ben-Yehuda O; Stone GW
    JACC Cardiovasc Interv; 2018 Jul; 11(13):1277-1286. PubMed ID: 29908967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
    Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention.
    Nusca A; Tuccinardi D; Proscia C; Melfi R; Manfrini S; Nicolucci A; Ceriello A; Pozzilli P; Ussia GP; Grigioni F; Di Sciascio G
    Cardiovasc Diabetol; 2019 Nov; 18(1):147. PubMed ID: 31706305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease: Thrombus burden assessed by optical coherence tomography.
    Yang X; Leesar MA; Ahmed H; Lendel V; Rodriguez G; Mutlu D; Cawich I; Prasad A; Oglesby M; Marmagkiolis K; Phillips NE; Jouke D; Michalek J; Liu Q; Milner T; McElroy A; Hoyt T; Feldman MD; Cilingiroglu M
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):778-784. PubMed ID: 29550045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.